Appili Therapeutics Inc. (APLIF)
USD 0.03
(0.0%)
USD 0.03
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 12.41 Million CAD | 7.47% |
| 2023 | 11.55 Million CAD | 107.62% |
| 2022 | 5.56 Million CAD | 138.96% |
| 2021 | 2.32 Million CAD | -3.59% |
| 2020 | 2.41 Million CAD | 0.0% |
| 2019 | 2.41 Million CAD | 3.95% |
| 2018 | 2.32 Million CAD | 94.78% |
| 2017 | 1.19 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 8.72 Million CAD | -24.51% |
| 2024 Q2 | 6.95 Million CAD | -20.21% |
| 2024 FY | 12.41 Million CAD | 7.47% |
| 2024 Q4 | 12.41 Million CAD | 5.22% |
| 2024 Q3 | 11.79 Million CAD | 69.56% |
| 2023 Q1 | 8.72 Million CAD | -24.51% |
| 2023 Q3 | 7.94 Million CAD | 14.15% |
| 2023 Q4 | 11.55 Million CAD | 45.43% |
| 2023 Q2 | 6.95 Million CAD | -20.21% |
| 2023 FY | 11.55 Million CAD | 107.62% |
| 2022 Q2 | 16.05 Million CAD | 165.75% |
| 2022 Q1 | 6.04 Million CAD | 8.6% |
| 2022 FY | 5.56 Million CAD | 138.96% |
| 2022 Q4 | 11.55 Million CAD | -2.07% |
| 2022 Q3 | 11.79 Million CAD | -26.54% |
| 2021 Q2 | 2.68 Million CAD | -18.29% |
| 2021 FY | 2.32 Million CAD | -3.59% |
| 2021 Q4 | 5.56 Million CAD | 33.58% |
| 2021 Q1 | 3.28 Million CAD | 40.93% |
| 2021 Q3 | 4.16 Million CAD | 55.33% |
| 2020 FY | 2.41 Million CAD | 0.0% |
| 2020 Q3 | 2.32 Million CAD | 19.95% |
| 2020 Q2 | 1.94 Million CAD | -14.87% |
| 2020 Q1 | 2.28 Million CAD | -5.6% |
| 2020 Q4 | 2.32 Million CAD | 0.01% |
| 2019 Q4 | 2.41 Million CAD | -30.97% |
| 2019 Q3 | 3.49 Million CAD | 0.0% |
| 2019 FY | 2.41 Million CAD | 3.95% |
| 2019 Q1 | - CAD | -100.0% |
| 2018 Q4 | 2.32 Million CAD | 0.0% |
| 2018 FY | 2.32 Million CAD | 94.78% |
| 2017 FY | 1.19 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 76.709% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -29.567% |
| SQZ Biotechnologies Company | 50.03 Million USD | 75.189% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 82.869% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 78.962% |
| Mesoblast Limited | 188.44 Million USD | 93.412% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -222.353% |
| Genus plc | 485 Million USD | 97.44% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -112.493% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -393.385% |
| Marizyme, Inc. | 26.67 Million USD | 53.459% |
| ContraFect Corporation | 32.53 Million USD | 61.836% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -226.715% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -526.615% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -224.355% |
| Intellipharmaceutics International Inc. | 12 Million USD | -3.384% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -5.408% |
| MultiCell Technologies, Inc. | 1617.67 USD | -767373.094% |
| Accustem Sciences Inc. | 1.07 Million USD | -1050.364% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 83.963% |
| EV Biologics, Inc. | 2.11 Million USD | -486.987% |
| Q BioMed Inc. | 8.13 Million USD | -52.653% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 85.03% |
| Neon Bloom, Inc. | 1.22 Million USD | -912.482% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -141.257% |
| Biomind Labs Inc. | 1.49 Million USD | -728.445% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 94.913% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 32.539% |
| Skye Bioscience, Inc. | 14.07 Million USD | 11.775% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -517.631% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -8637.241% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -31.157% |
| IMV Inc. | 37.93 Million USD | 67.271% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -6073.145% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -116.073% |
| GB Sciences, Inc. | 5.41 Million USD | -129.166% |
| Alpha Cognition Inc. | 7.16 Million USD | -73.281% |
| HST Global, Inc. | 593.59 Thousand USD | -1991.531% |
| CSL Limited | 18.62 Billion USD | 99.933% |
| Halberd Corporation | 728.71 Thousand USD | -1603.7% |
| Enzolytics Inc. | 365.26 Million USD | 96.601% |
| Resverlogix Corp. | 67.39 Million USD | 81.579% |
| Affymax, Inc. | 8.87 Million USD | -39.952% |
| SYBLEU INC | 681.41 Thousand USD | -1721.976% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1380.232% |
| argenx SE | 444.95 Million USD | 97.21% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 83.429% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -624.34% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -4.302% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -238.735% |
| AVAX Technologies, Inc. | 3.99 Million USD | -210.866% |
| Zenith Capital Corp. | 27.56 Thousand USD | -44933.124% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.064% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -5102.168% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -232.463% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1723.526% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 89.543% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -37.303% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -18449.78% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -765.857% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 75.3% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -357.848% |
| BioStem Technologies, Inc. | 15.9 Million USD | 21.94% |
| ONE Bio Corp. | 27.49 Million USD | 54.847% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2571.661% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -45156.377% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -885.963% |
| Agentix Corp. | 2.51 Million USD | -394.519% |
| LadRx Corporation | 2.2 Million USD | -464.191% |
| Cell Source, Inc. | 15.8 Million USD | 21.456% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -27676.942% |
| Regen BioPharma, Inc. | 5.45 Million USD | -127.484% |
| Regen BioPharma, Inc. | 5.45 Million USD | -127.484% |
| NovAccess Global Inc. | 7.86 Million USD | -57.939% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 49.83% |
| Itoco Inc. | 1.65 Million USD | -651.001% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -505.157% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -105.244% |
| Kadimastem Ltd | 3.5 Million USD | -254.227% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2845.001% |
| CytoDyn Inc. | 127.89 Million USD | 90.293% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -29602.103% |
| Mobile Lads Corp. | 1.31 Million USD | -845.201% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -692.605% |
| Qrons Inc. | 1.48 Million USD | -733.954% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -12.403% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1435.024% |
| Rebus Holdings, Inc. | 5.24 Million USD | -136.841% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -103.464% |
| International Stem Cell Corporation | 5.27 Million USD | -135.27% |
| Bioxytran, Inc. | 3.24 Million USD | -282.064% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1883.861% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -168.894% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 69.716% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 44.239% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -512.978% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -126.637% |
| Neutra Corp. | 973.52 Thousand USD | -1175.276% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 57.211% |
| PureTech Health plc | 125.58 Million USD | 90.114% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -230.444% |
| IXICO plc | 1.9 Million USD | -553.33% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 39.524% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 87.984% |
| CSL Limited | 18.62 Billion USD | 99.933% |
| Cellectis S.A. | 249.36 Million USD | 95.021% |